DK4324522T3 - Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion - Google Patents

Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion

Info

Publication number: DK4324522T3
Authority: DK; Denmark
Prior art keywords: methods; renal function; impaired renal; fabry patients; treating fabry
Prior art date: 2017-05-30

Application number

DK23219949.7T

Other languages

English (en)

Inventor

Jeff Castelli

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-30

Filing date

2018-05-30

Publication date

2026-03-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4324522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-30 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2026-03-16 Application granted granted Critical

2026-03-16 Publication of DK4324522T3 publication Critical patent/DK4324522T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK23219949.7T 2017-05-30 2018-05-30 Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion DK4324522T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762512458P	2017-05-30	2017-05-30
US201862626953P	2018-02-06	2018-02-06
EP23189734.9A EP4245366A3 (en)	2017-05-30	2018-05-30	Migalastat for treating fabry patients having renal impairment

Publications (1)

Publication Number	Publication Date
DK4324522T3 true DK4324522T3 (da)	2026-03-16

Family

ID=65803261

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK23219949.7T DK4324522T3 (da)	2017-05-30	2018-05-30	Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion
DK18733415.6T DK3630114T3 (da)	2017-05-30	2018-05-30	Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion
DK22165669.7T DK4062916T3 (da)	2017-05-30	2018-05-30	Behandling af fabry-patienter med specifikke mutationer
DK23219933.1T DK4327869T3 (da)	2017-05-30	2018-05-30	Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK18733415.6T DK3630114T3 (da)	2017-05-30	2018-05-30	Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion
DK22165669.7T DK4062916T3 (da)	2017-05-30	2018-05-30	Behandling af fabry-patienter med specifikke mutationer
DK23219933.1T DK4327869T3 (da)	2017-05-30	2018-05-30	Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion

Country Status (14)

Country	Link
EP (9)	EP3630114B9 (da)
CN (4)	CN111278438A (da)
DK (4)	DK4324522T3 (da)
ES (5)	ES3002433T3 (da)
FI (4)	FI4062916T3 (da)
HR (4)	HRP20260346T1 (da)
HU (2)	HUE069837T2 (da)
LT (4)	LT4324522T (da)
PL (4)	PL4062916T3 (da)
PT (4)	PT4062916T (da)
RS (4)	RS67861B1 (da)
SI (4)	SI4327869T1 (da)
SM (4)	SMT202600114T1 (da)
TW (4)	TWI894750B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220313670A1 (en) *	2019-06-11	2022-10-06	Amicus Therapeutics, Inc.	Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) *	2019-08-07	2022-04-08	아미쿠스 세라퓨틱스, 인코포레이티드	Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) *	2006-05-16	2017-09-26	Nat Institutes Of Health	Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en)	2007-03-30	2010-11-10	Amicus Therapeutics Inc	METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) *	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) *	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) *	2008-02-12	2009-08-20	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) *	2011-03-11	2012-09-20	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) *	2011-05-06	2012-11-08	Amicus Therapeutics Inc.	Quantitation of gl3 in urine
WO2018017721A1 (en)	2016-07-19	2018-01-25	Amicus Therapeutics, Inc.	Treatment of fabry disease in ert-naïve and ert-experienced patients
AU2018277756A1 (en)	2017-05-30	2020-01-23	Amicus Therapeutics, Inc.	Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) *	2017-07-19	2020-05-26	Амикус Терапьютикс, Инк.	Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

2018
- 2018-05-30 PL PL22165669.7T patent/PL4062916T3/pl unknown
- 2018-05-30 FI FIEP22165669.7T patent/FI4062916T3/fi active
- 2018-05-30 SM SM20260114T patent/SMT202600114T1/it unknown
- 2018-05-30 LT LTEP23219949.7T patent/LT4324522T/lt unknown
- 2018-05-30 CN CN201880043564.XA patent/CN111278438A/zh active Pending
- 2018-05-30 PL PL23219933.1T patent/PL4327869T3/pl unknown
- 2018-05-30 SI SI201831311T patent/SI4327869T1/sl unknown
- 2018-05-30 HR HRP20260346TT patent/HRP20260346T1/hr unknown
- 2018-05-30 EP EP18733415.6A patent/EP3630114B9/en active Active
- 2018-05-30 SI SI201831310T patent/SI4324522T1/sl unknown
- 2018-05-30 EP EP25176976.6A patent/EP4635496A1/en active Pending
- 2018-05-30 TW TW112150982A patent/TWI894750B/zh active
- 2018-05-30 CN CN202411682885.8A patent/CN119587544A/zh active Pending
- 2018-05-30 SM SM20240037T patent/SMT202400037T1/it unknown
- 2018-05-30 DK DK23219949.7T patent/DK4324522T3/da active
- 2018-05-30 TW TW112104527A patent/TW202322814A/zh unknown
- 2018-05-30 ES ES22165669T patent/ES3002433T3/es active Active
- 2018-05-30 DK DK18733415.6T patent/DK3630114T3/da active
- 2018-05-30 EP EP23219933.1A patent/EP4327869B1/en active Active
- 2018-05-30 RS RS20260301A patent/RS67861B1/sr unknown
- 2018-05-30 PT PT221656697T patent/PT4062916T/pt unknown
- 2018-05-30 PL PL23219949.7T patent/PL4324522T3/pl unknown
- 2018-05-30 ES ES24164126T patent/ES3052647T3/es active Active
- 2018-05-30 HU HUE22165669A patent/HUE069837T2/hu unknown
- 2018-05-30 RS RS20250010A patent/RS66376B1/sr unknown
- 2018-05-30 HR HRP20240061TT patent/HRP20240061T1/hr unknown
- 2018-05-30 SM SM20260113T patent/SMT202600113T1/it unknown
- 2018-05-30 FI FIEP18733415.6T patent/FI3630114T3/fi active
- 2018-05-30 EP EP22165669.7A patent/EP4062916B1/en active Active
- 2018-05-30 HU HUE18733415A patent/HUE065615T2/hu unknown
- 2018-05-30 SI SI201831193T patent/SI4062916T1/sl unknown
- 2018-05-30 EP EP24164126.5A patent/EP4374918B1/en active Active
- 2018-05-30 RS RS20260292A patent/RS67849B1/sr unknown
- 2018-05-30 TW TW110119149A patent/TWI775453B/zh active
- 2018-05-30 SM SM20250016T patent/SMT202500016T1/it unknown
- 2018-05-30 PT PT187334156T patent/PT3630114T/pt unknown
- 2018-05-30 FI FIEP23219949.7T patent/FI4324522T3/fi active
- 2018-05-30 CN CN202311285883.0A patent/CN117357524A/zh active Pending
- 2018-05-30 CN CN202510610323.0A patent/CN120732857A/zh active Pending
- 2018-05-30 RS RS20240113A patent/RS65230B1/sr unknown
- 2018-05-30 LT LTEP23219933.1T patent/LT4327869T/lt unknown
- 2018-05-30 ES ES18733415T patent/ES2970419T3/es active Active
- 2018-05-30 SI SI201831052T patent/SI3630114T1/sl unknown
- 2018-05-30 HR HRP20241738TT patent/HRP20241738T1/hr unknown
- 2018-05-30 EP EP23219922.4A patent/EP4327868A2/en not_active Withdrawn
- 2018-05-30 ES ES23219933T patent/ES3065413T3/es active Active
- 2018-05-30 DK DK22165669.7T patent/DK4062916T3/da active
- 2018-05-30 DK DK23219933.1T patent/DK4327869T3/da active
- 2018-05-30 EP EP23189734.9A patent/EP4245366A3/en not_active Withdrawn
- 2018-05-30 ES ES23219949T patent/ES3065434T3/es active Active
- 2018-05-30 EP EP22165647.3A patent/EP4062915A1/en not_active Withdrawn
- 2018-05-30 LT LTEPPCT/US2018/035032T patent/LT3630114T/lt unknown
- 2018-05-30 TW TW107118443A patent/TWI795408B/zh active
- 2018-05-30 PL PL18733415.6T patent/PL3630114T3/pl unknown
- 2018-05-30 PT PT232199497T patent/PT4324522T/pt unknown
- 2018-05-30 EP EP23219949.7A patent/EP4324522B1/en active Active
- 2018-05-30 FI FIEP23219933.1T patent/FI4327869T3/fi active
- 2018-05-30 PT PT232199331T patent/PT4327869T/pt unknown
- 2018-05-30 LT LTEP22165669.7T patent/LT4062916T/lt unknown
- 2018-05-30 HR HRP20260335TT patent/HRP20260335T1/hr unknown

Also Published As

Publication number	Publication date
TWI775453B (zh)	2022-08-21
DK3630114T3 (da)	2024-01-29
RS67849B1 (sr)	2026-03-31
SI4062916T1 (sl)	2025-04-30
EP4327869A3 (en)	2024-05-22
TW201900165A (zh)	2019-01-01
HRP20240061T1 (hr)	2024-03-29
EP4324522A2 (en)	2024-02-21
CN119587544A (zh)	2025-03-11
EP4635496A1 (en)	2025-10-22
ES2970419T3 (es)	2024-05-28
EP4062915A1 (en)	2022-09-28
HUE069837T2 (hu)	2025-04-28
CN117357524A (zh)	2024-01-09
FI4324522T3 (fi)	2026-03-09
SI3630114T1 (sl)	2024-03-29
LT4327869T (lt)	2026-03-25
PT4327869T (pt)	2026-03-12
SMT202400037T1 (it)	2024-03-13
EP4245366A9 (en)	2023-12-06
FI3630114T3 (fi)	2024-01-30
DK4062916T3 (da)	2025-01-13
FI4062916T3 (fi)	2025-01-10
EP4245366A2 (en)	2023-09-20
RS66376B1 (sr)	2025-02-28
EP4327869B1 (en)	2025-12-10
SMT202500016T1 (it)	2025-03-12
ES3052647T3 (en)	2026-01-12
EP4374918B1 (en)	2025-07-16
HUE065615T2 (hu)	2024-06-28
EP4245366A3 (en)	2023-11-29
PL4062916T3 (pl)	2025-03-17
EP4062916A1 (en)	2022-09-28
FI4327869T3 (fi)	2026-03-09
TWI795408B (zh)	2023-03-11
TWI894750B (zh)	2025-08-21
SMT202600114T1 (it)	2026-05-12
SMT202600113T1 (it)	2026-05-12
PT4324522T (pt)	2026-03-13
EP3630114B9 (en)	2026-05-20
HRP20260335T1 (hr)	2026-04-10
HRP20241738T1 (hr)	2025-02-28
EP4324522A3 (en)	2024-05-22
LT4324522T (lt)	2026-03-25
PT3630114T (pt)	2024-02-01
RS65230B1 (sr)	2024-03-29
LT3630114T (lt)	2024-02-12
EP4327869A2 (en)	2024-02-28
EP4374918A3 (en)	2024-08-14
EP4062916B1 (en)	2024-10-09
PL4327869T3 (pl)	2026-04-27
ES3002433T3 (en)	2025-03-06
PT4062916T (pt)	2025-01-13
ES3065434T3 (en)	2026-05-06
TW202440104A (zh)	2024-10-16
EP4374918A2 (en)	2024-05-29
SI4327869T1 (sl)	2026-05-29
EP3630114B1 (en)	2023-11-01
LT4062916T (lt)	2025-01-10
TW202322814A (zh)	2023-06-16
EP3630114A1 (en)	2020-04-08
CN111278438A (zh)	2020-06-12
SI4324522T1 (sl)	2026-05-29
PL4324522T3 (pl)	2026-04-27
CN120732857A (zh)	2025-10-03
EP4324522B1 (en)	2025-12-10
EP4327868A2 (en)	2024-02-28
PL3630114T3 (pl)	2024-03-25
DK4327869T3 (da)	2026-03-16
HRP20260346T1 (hr)	2026-04-24
TW202140000A (zh)	2021-11-01
RS67861B1 (sr)	2026-04-30
ES3065413T3 (en)	2026-05-06

Publication	Publication Date	Title
DK3448426T3 (da)	2025-06-30	Fremgangsmåder til behandling af patienter med familiær hyperkolesterolæmi
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3322722T3 (da)	2025-05-26	Midler, anvendelser og fremgangsmåder til behandling af synukleinopati
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
IL270956A (en)	2020-01-30	Methods of treating fabry patients having renal impairment
DK3580211T3 (da)	2021-01-25	2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
EP3256071C0 (en)	2026-01-14	AORTIC IMPLANT
DK3433266T3 (da)	2025-08-25	Fremgangsmåder til behandling af mitokondrieforstyrrelser
PL3512642T3 (pl)	2021-06-14	Rozwiązanie bezmłotkowe
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3507408T3 (da)	2021-04-06	Fremgangsmåde til fremstilling af nonwoven
DK3242947T3 (da)	2020-08-03	Genterapi og elektroporese til behandling af maligniteter
DK3331879T3 (da)	2020-08-10	Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3324824T3 (da)	2024-12-02	Fremgangsmåde til behandling af binokulare dysfunktioner
DK3513821T3 (da)	2020-09-07	Materiale til rensning af blod
DK3265087T3 (da)	2020-10-19	Fremgangsmåde til behandling med tradipitant
IL260414B (en)	2021-08-31	Automatic deskew using design files or inspection images
DK3393468T3 (da)	2022-12-19	Fremgangsmåder til behandling af en immundefektsygdom
EP3687670C0 (en)	2023-08-23	ARTIFICIAL KIDNEY DEVICE WITHOUT DIALYSATE
HUE053557T2 (hu)	2021-07-28	Eljárások akut vesekárosodás kezelésére
DK3334693T3 (da)	2019-10-07	Kontinuerlig fremgangsmåde og system til behandlingen af spildevand
DK3661510T3 (da)	2025-01-02	Fremgangsmåder til behandling af adfærdsændringer
DK3506956T3 (da)	2021-06-14	Lægemiddel, særlig til behandling af fistler
DK3448340T3 (da)	2020-06-08	Applikationshjælpemiddel til behandling af sår
DK3373931T3 (da)	2022-11-28	Heterocykliske forbindelser til behandling af sygdom